Britain's top health-guidance body has approved a simple spit test that could cut the average 11-year wait for an endometriosis diagnosis, a condition affecting roughly one in ten women worldwide.
The National Institute for Health and Care Excellence, the UK agency known as NICE, gave the green light earlier this month for a saliva-based diagnostic tool called Endotest to be used in clinicians' offices across England and Wales. The approval runs for three years. Rather than requiring invasive surgery to confirm the disease, Endotest checks a saliva sample for microRNAs, small molecular markers that can signal whether endometriosis is likely present.
For the roughly 190 million women worldwide who live with endometriosis, the approval marks a concrete step toward faster answers. Women may wait up to 11 years between their first symptoms and a formal diagnosis, Yale Medicine has reported. That gap leaves patients cycling through specialists, dismissed or misdiagnosed, while the disease progresses.
Until now, the gold standard for confirming endometriosis has been laparoscopic surgery, a procedure that requires anesthesia, recovery time, and a spot on an already crowded surgical calendar. The new test sidesteps that bottleneck. A clinician collects a saliva sample in the office, and the microRNA analysis flags whether endometriosis is likely.
NICE was clear on one point: Endotest is not meant to serve as a standalone diagnostic tool. It fits into a broader clinical picture. But even as a screening layer, it could spare women years of uncertainty and free up operating-room time for patients who need surgical treatment.
Dr. Gail Busby, a consultant gynaecologist at Manchester University NHS Foundation Trust, put the stakes plainly in a NICE press release:
"These tests are a game-changer because they give us answers much earlier, without the need for invasive surgery."
Busby added that the benefits ripple beyond any single patient:
"An earlier diagnosis doesn't just change one person's life, it frees up appointments and surgical slots for everyone waiting for care."
The diagnostic delay is not just a scheduling problem. It reflects a deeper failure inside the medical profession itself. Dr. Sheeva Talebian, a board-certified reproductive endocrinologist, has spoken bluntly about how often the condition slips through the cracks, even among specialists who should know better.
Talebian previously told the New York Post:
"Quite frankly, even amongst gynecologists, this disease is still not fully understood or recognized. Therefore, even a gynecologist may miss some of the varying symptoms and pass these women off to other specialists for testing."
That pattern, pain dismissed, patients shuffled from doctor to doctor, helps explain why the average wait stretches to a full decade. And the tools available have not kept pace with the need. Talebian was direct about the gap: "There is no good blood test or imaging modality that can detect endometriosis."
The consequences of late diagnosis can be severe. In advanced cases, chronic inflammation and scar tissue cause what doctors call a "frozen pelvis." Talebian described the condition in stark terms:
"In the most severe cases, we see what's called a frozen pelvis, which is when chronic inflammation and scar tissue cause the ovaries, bladder and bowel to fuse together, distorting your internal anatomy."
That is not a minor inconvenience. It is organ damage caused, in part, by years of missed or delayed diagnosis.
The NICE approval is limited to England and Wales and carries a three-year window, after which further review is presumably required. Several practical questions remain open. NICE did not specify, at least in the available reporting, what clinical criteria a doctor must meet before ordering the test, what the test costs, or whether the National Health Service will cover it.
Nor is it clear who manufactures Endotest, what its sensitivity and specificity numbers look like, or whether any regulatory body outside the UK, including the U.S. Food and Drug Administration, has the test under review. For the millions of American women living with undiagnosed endometriosis, a British approval is encouraging but not yet actionable.
Talebian herself has noted that the medical profession has long conditioned women to accept debilitating pain as normal. A saliva test will not fix that culture overnight. But it removes one of the profession's oldest excuses, that there was simply no reliable, noninvasive way to screen for the disease.
Women who have spent years hearing that their pain is in their heads deserve better than an 11-year wait for an answer. If a spit test can deliver that answer faster, the only real question is why it took this long.
